ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.86+0.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
ORIC focuses on advancing two lead clinical programs with stable management. The company aims to maintain cash runway into the second half of 2028 and beyond. Operating losses are managed around -$35 million per quarter, supporting development while controlling cash burn.
ORIC remains loss-making with no revenue and negative earnings expected through 2027. Cash burn could accelerate if clinical programs fail or costs rise. The company faces elevated risk with uncertain progress on its drug pipeline.
The stock price is about 37% below our valuation level and in line with the Street median. The market reflects uncertainty about ORIC's ability to generate revenue and sustain losses, while our view emphasizes the importance of cash runway and expense management.
Breaks if: Cash and investments fall short of sustaining operations into 2H 2028
Ensure sufficient cash and investments to fund operating plan through at least the second half of 2028.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a stable management team, but recent financial results have been weak, leading to a cautious outlook.
The market appears to have low expectations for ORIC, given its recent earnings misses and the elevated risk profile. There is a low level of fragility in the current market regime, suggesting that significant negative surprises may not be fully priced in.
Management is focused on advancing clinical trials and maintaining a sufficient cash runway, which is crucial for its operations. However, the company has a high probability of missing earnings expectations, which could further impact its performance.
The long-term thesis hinges on the outcomes of clinical trials and the overall health of the healthcare sector. Positive developments from key sector players could provide momentum, while negative guidance or economic downturns could weigh heavily on ORIC.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 of last 4 quarters. Cash and investments decreased from $419.7M in 2026-Q1 to $387.6M in 2026-Q2 but remain sufficient to fund operations into 2H 2028 as management expects. The trajectory shows delivering on maintaining runway despite cash burn.
“Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond”
“Cash and investments of approximately $420 million expected to provide runway into 2H 2028 and beyond”
“Cash and investments expected to provide runway into 2H 2028 and beyond”
“Cash and investments expected to provide runway into 2H 2028”
Breaks if: Failure or significant delay in lead clinical programs
Breaks if: Operating losses worsen significantly beyond -$40M per quarter
Control research and development and general administrative expenses while managing net losses as the company advances clinical programs.
Stated as a priority in 2 of last 2 quarters. R&D expenses rose from $24.6M in 2025-Q1 to $36.3M in 2026-Q2, with net losses increasing from $30.0M to $41.5M over the same period. This reflects increased investment in clinical programs, consistent with management's stated operational focus.
“R&D expenses were $36.3 million for the three months ended June 30, 2026”
“R&D expenses were $31.4 million for the three months ended March 31, 2026”
In the next 1 to 3 years, ORIC's performance will depend on its ability to navigate clinical developments and sector dynamics. Not investment advice.